Venetoclax

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`DRUG-VENETOCLAX`
Type	Drug
Aliases	VenclextaVenclyxtoВенетоклакс
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-AML` `DIS-CLL` `DIS-MDS-HR` `DIS-T-PLL`
Sources	`SRC-NCCN-AML-2025` `SRC-NCCN-BCELL-2025`

Drug Facts

Class	Selective BCL-2 inhibitor (BH3 mimetic)
Mechanism	Selectively binds BCL-2, displaces pro-apoptotic BH3 proteins, restores apoptosis in BCL-2-dependent cancer cells. Highly active in CLL (where CLL is BCL-2-addicted), AML, multiple myeloma. Substantial tumor lysis risk at initiation — strict 5-week dose ramp + TLS prophylaxis required.
Typical dosing	CLL 1L (CLL14 schedule): 5-week ramp 20 → 50 → 100 → 200 → 400 mg PO daily, then 400 mg daily continuous OR for 12 months total combined with obinutuzumab 6 cycles. AML / r/r MM use different schedules.
Ukraine registered	True
NSZU reimbursed	True
Ukraine last verified	2026-04-27

Warnings

Tumor lysis syndrome — fatal if not managed; mandatory TLS prophylaxis + ramp

Notes

Used in fixed-duration combos: VenO (venetoclax + obinutuzumab) 12 mo for CLL 1L (CLL14); MURANO for r/r CLL with rituximab. AML: lower-dose with azacitidine for unfit. Ukraine: registered, NOT НСЗУ reimbursed — major access barrier. Strict 5-week ramp-up + IV hydration + allopurinol + serial labs every 6-8 hours during first 3 doses of each ramp step for high-burden CLL — TLS deaths reported with skipped protocol.

Used By

Regimens

REG-AVO-CLL-1L - Acalabrutinib + Venetoclax + Obinutuzumab (AVO), fixed-duration 14 cycles (AMPLIFY)
REG-VEN-AZA-AML - Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule
REG-VENETOCLAX-ALEMTUZUMAB-TPLL - Venetoclax + alemtuzumab combination for r/r T-PLL (investigational)
REG-VENETOCLAX-OBINUTUZUMAB - Venetoclax + Obinutuzumab (VenO), 12 months fixed-duration (CLL14 schedule)
REG-VENETOCLAX-RITUXIMAB - Venetoclax + Rituximab (VenR), 24-month fixed-duration (MURANO schedule)